An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

Katherine Stemke-Hale, Ana Maria Gonzalez-Angulo, Ana Lluch, Richard M. Neve, Wen Lin Kuo, Michael Davies, Mark Carey, Zhi Hu, Yinghui Guan, Aysegul Sahin, W. Fraser Symmans, Lajos Pusztai, Laura K. Nolden, Hugo Horlings, Katrien Berns, Mien Chie Hung, Marc J. Van De Vijver, Vicente Valero, Joe Gray, René BernardsGordon Mills, Bryan T. Hennessy

Research output: Contribution to journalArticle

648 Citations (Scopus)

Abstract

Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor-positive (34.5%) and HER2-positive (22.7%) than in basal-like tumors (8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor-positive cancers. Unlike AKT1 mutations that were absent from cell lines, PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture. PIK3CA mutations did not have a significant effect on outcome after adjuvant tamoxifen therapy in 157 hormone receptor-positive breast cancer patients. PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were associated with significantly less and inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines. PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiology. PTEN loss rendered cells significantly more sensitive to growth inhibition by the PI3K inhibitor LY294002 than did PIK3CA mutations. Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes. The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer.

Original languageEnglish (US)
Pages (from-to)6084-6091
Number of pages8
JournalCancer Research
Volume68
Issue number15
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

Fingerprint

Proteomics
Phosphatidylinositol 3-Kinase
Breast Neoplasms
Mutation
Hormones
Tamoxifen
Tumor Cell Line
Cell Line
Neoplasms
Protein Array Analysis
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Mass Spectrometry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W. L., Davies, M., ... Hennessy, B. T. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Research, 68(15), 6084-6091. https://doi.org/10.1158/0008-5472.CAN-07-6854

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. / Stemke-Hale, Katherine; Gonzalez-Angulo, Ana Maria; Lluch, Ana; Neve, Richard M.; Kuo, Wen Lin; Davies, Michael; Carey, Mark; Hu, Zhi; Guan, Yinghui; Sahin, Aysegul; Symmans, W. Fraser; Pusztai, Lajos; Nolden, Laura K.; Horlings, Hugo; Berns, Katrien; Hung, Mien Chie; Van De Vijver, Marc J.; Valero, Vicente; Gray, Joe; Bernards, René; Mills, Gordon; Hennessy, Bryan T.

In: Cancer Research, Vol. 68, No. 15, 01.08.2008, p. 6084-6091.

Research output: Contribution to journalArticle

Stemke-Hale, K, Gonzalez-Angulo, AM, Lluch, A, Neve, RM, Kuo, WL, Davies, M, Carey, M, Hu, Z, Guan, Y, Sahin, A, Symmans, WF, Pusztai, L, Nolden, LK, Horlings, H, Berns, K, Hung, MC, Van De Vijver, MJ, Valero, V, Gray, J, Bernards, R, Mills, G & Hennessy, BT 2008, 'An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer', Cancer Research, vol. 68, no. 15, pp. 6084-6091. https://doi.org/10.1158/0008-5472.CAN-07-6854
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Research. 2008 Aug 1;68(15):6084-6091. https://doi.org/10.1158/0008-5472.CAN-07-6854
Stemke-Hale, Katherine ; Gonzalez-Angulo, Ana Maria ; Lluch, Ana ; Neve, Richard M. ; Kuo, Wen Lin ; Davies, Michael ; Carey, Mark ; Hu, Zhi ; Guan, Yinghui ; Sahin, Aysegul ; Symmans, W. Fraser ; Pusztai, Lajos ; Nolden, Laura K. ; Horlings, Hugo ; Berns, Katrien ; Hung, Mien Chie ; Van De Vijver, Marc J. ; Valero, Vicente ; Gray, Joe ; Bernards, René ; Mills, Gordon ; Hennessy, Bryan T. / An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. In: Cancer Research. 2008 ; Vol. 68, No. 15. pp. 6084-6091.
@article{2f8dbe07f16b466dbe153fcf97e80396,
title = "An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer",
abstract = "Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor-positive (34.5{\%}) and HER2-positive (22.7{\%}) than in basal-like tumors (8.3{\%}). AKT1 (1.4{\%}) and PTEN (2.3{\%}) mutations were restricted to hormone receptor-positive cancers. Unlike AKT1 mutations that were absent from cell lines, PIK3CA (39{\%}) and PTEN (20{\%}) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture. PIK3CA mutations did not have a significant effect on outcome after adjuvant tamoxifen therapy in 157 hormone receptor-positive breast cancer patients. PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were associated with significantly less and inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines. PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiology. PTEN loss rendered cells significantly more sensitive to growth inhibition by the PI3K inhibitor LY294002 than did PIK3CA mutations. Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes. The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer.",
author = "Katherine Stemke-Hale and Gonzalez-Angulo, {Ana Maria} and Ana Lluch and Neve, {Richard M.} and Kuo, {Wen Lin} and Michael Davies and Mark Carey and Zhi Hu and Yinghui Guan and Aysegul Sahin and Symmans, {W. Fraser} and Lajos Pusztai and Nolden, {Laura K.} and Hugo Horlings and Katrien Berns and Hung, {Mien Chie} and {Van De Vijver}, {Marc J.} and Vicente Valero and Joe Gray and Ren{\'e} Bernards and Gordon Mills and Hennessy, {Bryan T.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-07-6854",
language = "English (US)",
volume = "68",
pages = "6084--6091",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

AU - Stemke-Hale, Katherine

AU - Gonzalez-Angulo, Ana Maria

AU - Lluch, Ana

AU - Neve, Richard M.

AU - Kuo, Wen Lin

AU - Davies, Michael

AU - Carey, Mark

AU - Hu, Zhi

AU - Guan, Yinghui

AU - Sahin, Aysegul

AU - Symmans, W. Fraser

AU - Pusztai, Lajos

AU - Nolden, Laura K.

AU - Horlings, Hugo

AU - Berns, Katrien

AU - Hung, Mien Chie

AU - Van De Vijver, Marc J.

AU - Valero, Vicente

AU - Gray, Joe

AU - Bernards, René

AU - Mills, Gordon

AU - Hennessy, Bryan T.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor-positive (34.5%) and HER2-positive (22.7%) than in basal-like tumors (8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor-positive cancers. Unlike AKT1 mutations that were absent from cell lines, PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture. PIK3CA mutations did not have a significant effect on outcome after adjuvant tamoxifen therapy in 157 hormone receptor-positive breast cancer patients. PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were associated with significantly less and inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines. PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiology. PTEN loss rendered cells significantly more sensitive to growth inhibition by the PI3K inhibitor LY294002 than did PIK3CA mutations. Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes. The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer.

AB - Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor-positive (34.5%) and HER2-positive (22.7%) than in basal-like tumors (8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor-positive cancers. Unlike AKT1 mutations that were absent from cell lines, PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture. PIK3CA mutations did not have a significant effect on outcome after adjuvant tamoxifen therapy in 157 hormone receptor-positive breast cancer patients. PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were associated with significantly less and inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines. PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiology. PTEN loss rendered cells significantly more sensitive to growth inhibition by the PI3K inhibitor LY294002 than did PIK3CA mutations. Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes. The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=51049118140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51049118140&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-6854

DO - 10.1158/0008-5472.CAN-07-6854

M3 - Article

C2 - 18676830

AN - SCOPUS:51049118140

VL - 68

SP - 6084

EP - 6091

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -